Nucletron, an Elekta Company, Receives US FDA 510(k) Clearance for Esteya Electronic Brachytherapy System for Treating Skin Cancer

Stockholm, October 2 – Esteya®, an electronic brachytherapy system, has received
510(k) clearance from the US Food and Drug Administration (FDA), enabling
medical centers in the United States to offer their patients with skin cancer a
new treatment option.
Esteya is a new approach for high precision skin cancer treatment. The system
relies on a small, high dose rate (HDR) to apply radiation directly to the
cancerous site. This direct delivery enables Esteya to focus more therapeutic
radiation on the disease target and to minimize radiation to surrounding tissues
and organs. Electronic brachytherapy is well-suited for treating skin lesions,
such as basal cell or squamous cell carcinoma, achieving a greater than 95
percent cure rate for this technique1.

“The interest in Esteya among radiation oncologists during the American Society
for Radiation Oncology annual meeting last week in Atlanta was encouraging,”
says John Lapré, Executive Vice President, Brachytherapy at Elekta. “They
appreciated the efficient workflow, easy patient set-up, and the short treatment
delivery time. They also cited the accessibility of Esteya – due to its compact
design and reduced shielding requirements – allowing treatment to occur
virtually anywhere patients are seen within the clinic.”

The first installations of Esteya in the United States are scheduled to occur in
the next few months.

To learn more about Esteya, visit Esteya.com (http://www.esteya.com/).

Availability of Esteya in target markets is dependent on regulatory admissions
and approvals.

# # #

For further information, please contact:
Johan Andersson, Director, Investor Relations, Elekta AB
Tel: +46 702 100 451, email: johan.andersson@elekta.com
Time zone: CET: Central European Time

Michelle Joiner, Director, Global Public Relations and Brand Management, Elekta
Tel: +1 770-670-2447, email: michelle.joiner@elekta.com
Time zone: ET: Eastern Time

About Elekta
Elekta is a human care company pioneering significant innovations and clinical
solutions for treating cancer and brain disorders. The company develops
sophisticated, state-of-the-art tools and treatment planning systems for
radiation therapy, radiosurgery and brachytherapy, as well as workflow enhancing
software systems across the spectrum of cancer care. Stretching the boundaries
of science and technology, providing intelligent and resource-efficient
solutions that offer confidence to both healthcare providers and patients,
Elekta aims to improve, prolong and even save patient lives.

Today, Elekta solutions in oncology and neurosurgery are used in over 6,000
hospitals worldwide. Elekta employs around 3,500 employees globally. The
corporate headquarters is located in Stockholm, Sweden, and the company is
listed on the Nordic Exchange under the ticker EKTAb. Website: www.elekta.com.

_____________________________________

1 Bhatnagar A. Nonmelanoma skin cancer treated with electronic brachytherapy:
results at 1 year. Brachytherapy. 2013 Mar-Apr;12(2):134-40.